🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 22 of 173

  1. US 11634683

    Non-enzymatic method and milling device

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11634691

    Compositions and methods of treatment

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11634507

    Dendritic gold nanoparticles and methods of synthesis

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11628229

    Method of synthesizing 18F radiolabeled biomolecular agents

    Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11629122

    Linkers for antibody drug conjugates

    Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11628010

    Selective fat removal using photothermal heating

    Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11629167

    Betulastatin compounds

    Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11628146

    Estrogen receptor ligand treatment for neurodegenerative diseases

    Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11629372

    Random heteropolymers preserve protein function in foreign environments

    Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11622954

    Estrogen receptor ligands, compositions and methods related thereto

    Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11623010

    Pharmaceutical carrier in the preparation of an anti-diabetic pharmaceutical composition and methods for treatment

    Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11623927

    Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules

    Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11618888

    Tumor-selective E1A and E1B mutants

    Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11617761

    Methods for treating NLRP3 inflammasome-associated diseases, and methods of identifying agents useful therefor

    Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11617771

    Oral composition comprising lactic acid bacteria for regulating immune responses and methods related thereto

    Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11617788

    Viral promoters and compositions and methods of use thereof

    Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11617766

    Notch receptors with hinge domain

    Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11617796

    Conjugate of minoxidil and peptide

    Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11613544

    Substituted imidazo[1,5-a]pyrazines for modulation of IRE1

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11613758

    Engineered bacteria for production and release of therapeutics

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11612663

    Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11613735

    Methods for reprograming non-hepatocyte cells into hepatocyte cells

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11612580

    Compositions for inhibiting 3′ repair exonuclease 2 and methods of screening for such compositions

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11613528

    Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11612870

    Microencapsulation of chemicals and bioactives by in situ complex coacervation during spray drying

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11613739

    Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cells

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11612675

    Fish skin biologic bandage

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11613502

    Core-shell ceramic particle colloidal gel and solid oxide fuel cell electrolyte

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11608503

    RNA targeting of mutations via suppressor tRNAs and deaminases

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11607557

    Devices and systems for treating pain based on light therapy

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11607427

    Method for chemoselection

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11608367

    Peptides for angiogenic therapy

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11607387

    Efficient aqueous encapsulation and controlled release of bioactive agents

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11608308

    Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11607414

    Small molecule inhibitors of EGFR and PI3K

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11607464

    Compositions and methods for the treatment and imaging of cancer

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11608378

    Antibodies that bind integrin AVB8 and uses thereof

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11603365

    Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1H-1,2,3-triazole-4-carboxamide

    Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11602556

    Insulin mimotopes and methods of using the same

    Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11602551

    Use of inosine for the treatment of t-reg deficiency

    Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11603376

    Compositions and methods for treating cancer

    Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11603412

    Antibodies against CDCP1 for the treatment and detection of cancer

    Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11602568

    Engineered B lymphocytes and compositions having micro-RNA and methods for making and using them

    Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11603392

    Vault particles having a modified R8 flexible region

    Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11597916

    Nicotine degrading enzyme variants

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11597727

    Inhibitors of integrin alpha 2 beta 1 and methods of use

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11597749

    Peptide compositions and methods of use

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11597773

    CD6 antibody for treatment of T-cell mediated diseases or disorders

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.